A multimodal MRI radiomics and deep learning model outperformed traditional models in predicting 5- and 7-year survival for breast cancer patients receiving neoadjuvant chemotherapy.
Key Details
- 1Study involved 216 women with breast cancer post-neoadjuvant chemotherapy.
- 2Model integrated MRI radiomics, pathology, and clinical data using deep learning.
- 3The deep feature-based patho-radiomic model achieved AUCs of 0.89 (training) and 0.82 (test) for 5-year survival, and 0.91 (training) and 0.87 (test) for 7-year survival.
- 4Clinical-only models showed lower AUCs (0.4–0.53 for 5-years; 0.45–0.53 for 7-years).
- 5Traditional clinical and molecular markers (ER, HER2, TNBC) did not significantly predict survival in this cohort.
- 6Authors advocate for prospective studies to guide clinical decisions using the model.
Why It Matters
This research demonstrates the power of combining imaging, pathology, and clinical data through AI to provide more accurate long-term prognostic tools in oncology, surpassing traditional clinical or single-modality models. Improved risk stratification could optimize therapeutic decision-making and patient counseling in breast cancer care.
Source
AuntMinnie
Related News
•Radiology Business
Study Highlights Limitations of AI in Prostate MRI Screening
New research points to several shortcomings in implementing AI for MRI-based prostate cancer screening.
•AuntMinnie
Deep Learning Model Predicts Brain Tumor MRI Enhancement Without Gadolinium
German researchers developed a deep learning approach to predict MRI contrast enhancement in brain tumors without the need for gadolinium-based agents.
•HealthExec
Stanford Study: LLM-Generated Hospital Notes Safe, Aid Physician Wellbeing
Stanford research shows agentic LLMs can safely draft hospital discharge summaries, reducing physician burnout with minimal risk of patient harm.